Abstract
Our findings demonstrate that FMR1 promotes gastric cancer cell proliferation, migration, and invasion through c-MYC signaling, suggesting that FMR1 may serve as a potential prognostic biomarker and therapeutic target for gastric cancer.
Introduction
Gastric cancer (GC) remains a significant global health burden, characterized by high mortality rates often linked to late-stage diagnosis and limited therapeutic options. While the Fragile X Mental Retardation 1 (FMR1) gene is traditionally recognized for its role in neurodevelopmental disorders like Fragile X syndrome, recent research has begun to uncover its "moonlighting" functions in oncology. This study investigates the oncogenic role of FMR1 in gastric cancer, exploring its potential as a prognostic biomarker and its underlying molecular mechanisms.
Methods
The researchers utilized a comprehensive approach combining bioinformatics and experimental validation:
- Bioinformatics & Single-Cell Analysis: Data from TCGA-STAD and the TIMER2.0 platform were analyzed. Single-cell RNA sequencing (GSE183904) was used to map the cellular landscape of 36 gastric samples, employing the inferCNV algorithm to distinguish malignant cells.
- Functional Assays: FMR1 expression was manipulated using siRNA/shRNA and lentiviral vectors in GC cell lines (SNU-484, AGS). Proliferation, migration, and invasion were assessed via CCK-8, wound healing, and Transwell assays.
- Mechanistic Studies: Protein-protein interactions were confirmed via Co-Immunoprecipitation (Co-IP), and protein stability was evaluated using Cycloheximide (CHX) chase assays and proteasome inhibition with MG132.
Key Results
A primary finding of the study is the significant upregulation of FMR1 in gastric cancer tissues compared to healthy mucosa. Analysis of bulk transcriptomic data revealed a marked increase in FMR1 expression in tumor samples.
This trend was further validated through paired analysis of samples from the same patients, confirming that FMR1 levels are consistently higher in the malignant environment.
Functional experiments demonstrated that silencing FMR1 significantly inhibited the proliferation, migration, and invasion of GC cells. Conversely, high FMR1 levels were associated with poorer patient outcomes, with a Hazard Ratio of 1.54 for overall survival.
The c-MYC Stabilization Mechanism
The study uncovered a critical molecular "handshake" between FMRP (the protein product of FMR1) and c-MYC, a well-known oncogenic master regulator. Rather than simply increasing c-MYC production, FMRP physically binds to c-MYC, shielding it from proteasomal degradation. CHX chase assays confirmed that c-MYC degrades rapidly when FMR1 is knocked down, a process that can be halted by the proteasome inhibitor MG132. This stabilization of c-MYC drives the aggressive phenotype of gastric cancer cells and contributes to an immunosuppressive "cold" tumor microenvironment by reducing the infiltration of beneficial immune cells like Tregs and monocytes.
Conclusion and Future Directions
FMR1 acts as a potent oncogene in gastric cancer by stabilizing the c-MYC protein. While these findings highlight FMR1 as a promising prognostic biomarker and indirect target for c-MYC, the study is limited by a lack of in vivo validation and clinical stratification by Lauren classification. Future work should focus on developing therapeutic strategies to disrupt the FMRP/c-MYC interaction, potentially overcoming the "undruggable" nature of c-MYC itself.
Summary updated